NASDAQ · SLS
SELLAS Life Sciences Group, Inc.
$10.16-$0.23 (-2.17%)
SELLAS Life Sciences Group, Inc.’s quoted price sits in the upper half of its reported 52-week range, 36.05% below the high.
Loading market information…
NASDAQ · EPRX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Eupraxia Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 22.21% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Eupraxia Pharmaceuticals Inc.’s next earnings report is currently expected on Nov 3, 2026, with estimated earnings per share of -$0.26. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Eupraxia Pharmaceuticals Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 | Mar 20, 2025 | -$0.21-16.67% vs estimate | $0.00 |
|---|
| Q3 2024 | Nov 7, 2024 | -$0.17-30.05% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 4 contributors · Median target $17.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$10.16-$0.23 (-2.17%)
SELLAS Life Sciences Group, Inc.’s quoted price sits in the upper half of its reported 52-week range, 36.05% below the high.
€11.40-€0.06 (-0.52%)
Genfit S.A.’s quoted price sits in the upper half of its reported 52-week range, 26.36% below the high.
$3.14-$0.07 (-2.18%)
Nautilus Biotechnolgy, Inc.’s quoted price sits in the upper half of its reported 52-week range, 27.15% below the high.
$6.09+$0.10 (+1.67%)
Orchestra BioMed Holdings, Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.31% below the high.
$6.75+$0.06 (+0.9%)
Cartesian Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 56.65% below the high.
$3.73+$0.02 (+0.54%)
Inventiva S.A.’s quoted price sits in the lower half of its reported 52-week range, 48.83% below the high.
$13.86+$0.30 (+2.21%)
MediWound Ltd.’s quoted price sits in the lower half of its reported 52-week range, 29.64% below the high.
$2.52+$0.03 (+1.2%)
Protara Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 67.77% below the high.
